Friday, 17 Nov 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
23 Oct 2017 Social H Zoster inactive vaccine Shingrix FDA approved for use in adults >50yrs, >90% protection, 2 shots 2 mos apart https://t.co/c5uT04AtOw
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar https://t.co/IenWgRZUQL
18 Oct 2017 Social In a transition/switch study, SB2(infliximab biosimilar) was equal in efficacy & safety to ref infliximab for 78 wks https://t.co/qSnIoJuTG9
18 Oct 2017 Social Janssen halts anti-IL6 sirukumab development citing FDA rejection and need for more clinical data. https://t.co/3SLehEbLO0
16 Oct 2017 Social RT @USMerckProducts: Biosimilars are a new development in biologic medicines. To learn more, visit: https://t.co/mzo2DfBqKU https://t.co/TT…
11 Oct 2017 Social Multicenter study of135 JIA pts who stopped biologic - 76% flared; more if W/D tried before 2 years of remission. https://t.co/Fn0YXPUGkO
05 Oct 2017 News Patterns of Biologic Use During Autoimmune Pregnancy
25 Sep 2017 News Sirukumab Turned Down by FDA
20 Sep 2017 News Rituximab Efficacy in IgG4 Related Disease
20 Sep 2017 Social Pfizer takes Janssen to Court over infliximab competitive contracting practices ; claiming they are being "boxed out"https://t.co/JjVrLQGFia
13 Sep 2017 Social Sandoz announces FDA will review its biosimilar version of rituximab https://t.co/80E1jopxqd
11 Sep 2017 News Jak Inhibition May Ameliorate Pruritus
08 Sep 2017 News Biologic Use in Adult-Onset Still's Disease
07 Sep 2017 Social An approved biosimilar by regulatory authorities neither better nor worse in efficacy/safety to its bio-originator. https://t.co/cxWtoUsmwW
07 Sep 2017 News New Recommendations on Biosimilar Use
07 Sep 2017 Social In 10yrs MTX/biologic use increased (40%/1.7% to 64%/27%) & rate of ortho surgery dropped (72 to 51/1000 pts in 2014 https://t.co/IE72n2YMPB
06 Sep 2017 Social US patent office has issued two patents for janus kinase(JaK) inhibitors for hair loss. https://t.co/TReKaoFUwy
30 Aug 2017 News Turnabout for Baricitinib
29 Aug 2017 Social 25 studies shows low risk of HBV reactivation (1.6%) w/ resolved HBV - not changed by TNFi, other biologics, DMARDs https://t.co/wzjikRHPFh
28 Aug 2017 Social Severe (ocular) Behcets study: ~half respond to TNF inhib but only half these stay in remission w/ TNFi withdrawal https://t.co/a2oGZADlle